Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Penn STEM Times.
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
August 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
September 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 |
Press releases published on July 29, 2025
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
GlobeNewswire
·
July 29, 2025
SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic …
Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease
GlobeNewswire
·
July 29, 2025
- Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration - Trial to assess safety, PK and detect early signs of efficacy - Initial data expected in mid-2026 SACRAMENTO, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- …
GigaCloud Technology Inc. Expands Global Fulfillment Network with New Facility in Germany
GlobeNewswire
·
July 29, 2025
EL MONTE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc. (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced that one of its subsidiaries …
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
GlobeNewswire
·
July 29, 2025
SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the …
Vivex Biologics, Inc. Completes Subject Enrollment for its ASCEND Trial Evaluating VIA Disc NP™ for Symptomatic Disc Degeneration
GlobeNewswire
·
July 29, 2025
MIAMI, July 29, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced that it has completed subject enrollment in its ASCEND clinical trial evaluating VIA Disc NP for symptomatic …
AgEagle Aerial Systems Announces First Sale of Drones in Thailand
GlobeNewswire
·
July 29, 2025
First Sale in Southeast Asia lays foundation for manufacturer’s presence in region WICHITA, Kan., July 29, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE: UAVS), a leading provider of advanced drone and aerial imaging solutions, is proud to …
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
GlobeNewswire
·
July 29, 2025
Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company’s Phase 1b clinical trial design and optimization of biomarkers in AD Progress with trial …
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
GlobeNewswire
·
July 29, 2025
– ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $625 - $640 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis …
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
GlobeNewswire
·
July 29, 2025
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on …
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
GlobeNewswire
·
July 29, 2025
~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 topline three-year data in September 2025 ~ ~ Presented …
WAIC 2025: GPTBots Multi-Agent Platform Turns AI Tools into Collaborative Teams
GlobeNewswire
·
July 29, 2025
HONG KONG, July 29, 2025 (GLOBE NEWSWIRE) -- The highly anticipated 2025 World Artificial Intelligence Conference (WAIC) is underway in Shanghai, bringing together global leaders in AI innovation. GPTBots.ai, a leading enterprise-grade AI agent building …
Energous Wireless Power Solutions Reports Second Quarter 2025 Results
GlobeNewswire
·
July 29, 2025
- Reports Revenue of $1 Million - Highest Quarterly Revenue Since 2016 - - Accounts for Lowest Quarterly Net Loss in the last Decade - - Announces $4 million Order Backlog - SAN JOSE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Energous Corporation d/b/a …
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
GlobeNewswire
·
July 29, 2025
– LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community – – Over 800 patients enrolled across the LUGANO and …
Accelsius Demonstrates Strong Momentum in First Half of 2025 with 5x Growth in Data Center Deployments
GlobeNewswire
·
July 29, 2025
Expanded into European and Canadian markets through strategic partnerships Selected as key contributor to prestigious U.S. Department of Energy ARPA-E COOLERCHIPS project, validating technology leadership in next-generation cooling Doubled product …
Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025
GlobeNewswire
·
July 29, 2025
NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, …
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
GlobeNewswire
·
July 29, 2025
BEDFORD, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, …
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
GlobeNewswire
·
July 29, 2025
Boca Raton, July 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be published on the …
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
GlobeNewswire
·
July 29, 2025
― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious adverse events (SAEs) ― ― Observed robust and rapid pan- …
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
GlobeNewswire
·
July 29, 2025
― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF based on an …
チップモス (ChipMOS)、2025年第2四半期決算説明会開催のお知らせ
GlobeNewswire
·
July 29, 2025
台湾、新竹, July 29, 2025 (GLOBE NEWSWIRE) -- 半導体組み立て・テストのアウトソーシングサービス (OSAT) 分野における業界リーダーであるチップモス・テクノロジーズ (ChipMOS TECHNOLOGIES INC.) (以下「ChipMOS」または「当社」) (台湾証券取引所：8150、NASDAQ：IMOS) は本日、2025年8月12日 (火)に、2025年第2 …